CA1336826C - Chimeric antibody with specificity to human b cell surface antigen - Google Patents

Abstract

A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA
polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses. The chimeric antibody of the invention can be utilized for passive immunization without negative immune reactions, and also in immunodiagnostic assays and kits.

Description

336~26 TITLE OF THE INVENTION

C~TM~TC ANTIBODY WITH SPECIFICITY TO HUMAN
B CELL SURFACE ANTIGEN

BACKGROUND OF THE INVENTION

Field of the Invention This invention relates to recombinant DNA methods of preparing an antibody with specificity for an antigen on the surface of human B cells, genetic sequences coding therefor, as well as methods of obtaining such sequences.

Background Art The application of cell-to-cell fusion for the production of monoclonal antibodies by Kohler and Milstein (Nature (London), 256: 495, 1975) spawned a revolution in biology equal in impact to that from the ~' ,~

invention of recombinant D~A cloning. Monoclonal antibodies produced from hybridomas are already widely used in clinical and basic scientific studies. Appli-cations of human monoclonal antibodies produced by human hybridomas hold great promise for the treatment of cancer, viral and microbial infections, certain immunodeficiencies with diminished antibody produc-tion, and other diseases and disorders of the immune system.
Unfortunately, a number of obstacles exist with respect to the development of human monoclonal anti-bodies. This is especially true when attempting to develop therapeutically useful monoclonal antibodies which define human cell surface antigens. Many of these human cell surface antigens are not recognized as foreign antigens by the human immune system; there-fore, these antigens are not immunogenic in man. By contrast, human cellular antigens which are immuno-genic in mice can be used for the production of mouse monoclonal antibodies that specifically recognize the human antigens. Although such antibodies may be used therapeutically in man, repeated injections of "foreign" antibodies, such as a mouse antibody, in humans, can lead to harmful hypersensitivity reactions as well as increased rate of clearance of the circu-lating antibody molecules so that the antibodies do not reach their target site. Furthermore, mouse monoclonal antibodies may lack the ability to efficiently interact with human effector cells as assessed by functional assays such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytolysis (CDC).

Another problem faced by immunologists is that most human monoclonal antibodies obtained in cell cul-ture are of the IgM type. When it is desirable to obtain human monoclonals of the IgG type, however, it has been necessary to use such techniques as cell sorting to identify and isolate the few cells which are producing antibodies of the IgG or other type from the majority producing antibodies of the IgM type. A
need therefore exists for an efficient method of switching antibody classes, for any given antibody of a predetermined or desired antigenic specificity.
The present invention bridges both the hybridoma and genetic engineering technologies to provide a quick and efficient method, as well as products de-rived therefrom, for the production of a chimeric human/non-human antibody.
The chimeric antibodies of the present invention embody a combination of the advantageous characteris-tics of monoclonal antibodies derived from mouse-mouse hybridomas and of human monoclonal antibodies. The chimeric monoclonal antibodies, like mouse monoclonal antibodies, can recognize and bind to a human target antigen; however, unlike mouse monoclonal antibodies, the species-specific properties of the chimeric anti-bodies will avoid the induction of harmful hypersen-sitivity reactions and may allow for resistance to clearance when used in humans in vivo. Also, the inclusion of appropriate human immunoglobulin sequences can result in an antibody which efficiently interacts with human effector cells in vivo to cause tumor cell lysis and the like. Moreover, using the methods disclosed in the present invention, any desired antibody isotype can be conferred upon a particular antigen combining site.

INFORMATION DISCLOSURE STATEMENT
Approaches to the problem of producing chimeric antibodies have been published by various authors.
Morrison, S. L. et al., Proc. Natl. Acad. Sci., USA, 81: 6851-6855 (November 1984), describe the pro-duction of a mouse-human antibody molecule of defined antigen binding specificity, produced by joining the variable region genes of a mouse antibody-producing myeloma cell line with known antigen binding speci-ficity to human immunoglobulin constant region genes using recombinant DNA techniques. Chimeric genes were constructed, wherein the heavy chain variable region exon from the myeloma cell line S107 were joined to human IgGl or IgG2 heavy chain constant region exons, and the light chain variable region exon from the same myeloma to the human kappa light chain exon. These genes were transfected into mouse myeloma cell lines.
Transformed cells producing chimeric mouse-human antiphosphocholine antibodies were thus developed.
Morrison, S. L. et al., European Patent Publica-tion No. 173494 (published March 5, 1986), disclose chimeric "receptors" (e.g. antibodies) having variable regions derived from one species and constant regions derived from another. Mention is made of utilizing cDN~ cloning to construct the genes, although no de-tails of cDNA cloning or priming are shown. (see pp 5, 7 and 8).

~, .~-Boulianne, G. L. et al., Nature, 312: 643 (Decem-ber 13, 1984), also produced antibodies consisting of mouse variable regions joined to human constant re-gions. They constructed immunoglobulin genes in which the DNA segments encoding mouse variable regions spe-cific for the hapten trinitrophenyl (TNP) were joined to segments encoding human m and kappa constant re-gions. These chimeric genes were expressed as func-tional TNP binding chimeric IgM.
For a commentary on the work of Boulianne et al.
and Morrison et al., see Munro, Nature, 312: 597 (December 13, 1984), Dickson, Genetic Engineering News, S, No. 3 (March 1985), or Marx, Science, 229:
455 (August 1985).
Neuberger, M. S. et al., Nature, 314: 268 (March 25, 1985), also constructed a chimeric heavy chain immunoglobulin gene in which a DNA segment encoding a mouse variable region specific for the hapten 4-hy-droxy-3-nitrophenacetyl (NP) was joined to a segment encoding the human epsilon region. When this chimeric gene was transfected into the J558L cell line, an antibody was produced which bound to the NP hapten and had human IgE properties.
Neuberger, M.S. et al., have also published work showing the preparation of cell lines that secrete hapten-specific antibodies in which the Fc portion has been replaced either with an active enzyme moiety (Williams, G. and Neuberger, M.S. Gene 43:319, 1986) or with a polypeptide displaying c-myc antigenic determinants (Nature, 312:604, 1984).
Neuberger, M. et al., PCT Publication WO 86/01533, (published March 13, 1986) also disclose production of chimeric antibodies (see p. 5) and suggests, among the technique's many uses the concept of "class switching"
(see p. 6).
Taniguchi, M., in European Patent Publication No.
171 496 (published February 19, 1985) discloses the production of chimeric antibodies having variable re-gions with tumor specificty derived from experimen-tal animals, and constant regions derived from human.
The corresponding heavy and light chain genes are pro-duced in the genomic form, and expressed in mammalian cells.
Takeda, S. et al., Nature, 314: 452 (April 4, 1985~ have described a potential method for the con-struction of chimeric immunoglobulin genes which have intron sequences removed by the use of a retrovirus vector. However, an unexpected splice donor site caused the deletion of the V region leader sequence.
Thus, this approach did not yield complete chimeric antibody molecules.
Cabilly, S. et al., Proc. Natl. Acad. Sci., USA, 81: 3273-3277 (June 1984), describe plasmids that di-rect the synthesis in E. coli of heavy chains and/or light chains of anti-carcinoembryonic antigen (CEA) antibody. Another plasmid was constructed for expres-sion of a truncated form of heavy chain (~d') fragment in E. coli. Functional CEA-binding activity was ob-tained by in vitro reconstitution, in E. coli extracts, of a portion of the heavy chain with light chain.
Cabilly, S., et al., European Patent Publication 125023 (published November 14, 1984) describes chimer-ic immunoglobulin genes and their presumptive products as well as other modified forms. On pages 21, 28 and 33 it discusses cDNA cloning and priming.
Boss, M. A., European Patent Application 120694 (published October 3, 1984) shows expression in E.
coli of non-chimeric immunoglobulin chains with 4-nitrophenyl specificity. There is a broad descrip-tion of chimeric antibodies but no details (see p. 9).
Wood, C. R. et al., Nature, 314: 446 (April, 1985) describe plasmids that direct the synthesis of mouse anti-NP antibody proteins in yeast. Heavy chain m antibody proteins appeared to be glycosylated in the yeast cells. When both heavy and light chains were synthesized in the same cell, some of the protein was assembled into functional antibody molecules, as de-tected by anti-NP binding activity in soluble protein prepared from yeast cells.
Alexander, A. et al., Proc. Nat. Acad. Sci. USA, 79: 3260-3264 (1982), describe the preparation of a cDNA sequence coding for an abnormally short human Ig qamma heavy chain (OMM qamma3 HCD serum protein) con-taining a 19- amino acid leader followed by the first 15 residues of the V region. An extensive internal deletion removes the remainder of the V and the entire CHl domain. This is cDNA coding for an internally deleted molecule.
Dolby, T. W. et al., Proc. Natl. Acad. Sci., USA, 77: 6027-6031 (1980), describe the preparation of a cDNA sequence and recombinant plasmids containing the same coding for mu and kappa human immunoglobulin polypeptides. One of the recombinant DNA molecules contained codons for part of the CH3 constant region domain and the entire 3' noncoding sequence.

Seno, M. et al., Nucleic Acids Research, 11: 719-726 (1983), describe the preparation of a cDNA
sequence and recombinant plasmids containing the same coding for part of the variable region and all of the constant region of the human IgE heavy chain (epsilon chain).
Rurokawa, T. et al., ibid, 11: 3077-3085 (1983), show the construction, using cDNA, of three expression plasmids coding for the constant portion of the human IgE heavy chain.
Liu, F. T. et al., Proc. Nat. Acad. Sci., USA, 81:
5369-5373 (September 1984), describe the preparation of a cDNA sequence and recombinant plasmids containing the same encoding about two-thirds of the CH2, and all of the CH3 and CH4 domains of human IgE heavy chain.
Tsujimoto, Y. et al., Nucleic Acids Res., 12:
8407-8414 (November 1984), describe the preparation of a human V lambda cDNA sequence from an Ig lambda-pro-ducing human Burkitt lymphoma cell line, by taking advantage of a cloned constant region gene as a primer for cDNA synthesis.
Murphy, J., PCT Publication WO 83/03971 (published November 24, 1983) discloses hybrid proteins made of fragments comprising a toxin and a cell-specific li-gand (which is suggested as possibly being an anti-body).
Tan, et al., J. Immunol. 135:8564 (November, 1985), obtained expression of a chimeric human-mouse immunoglobulin genomic gene after transfection into mouse myeloma cells.
Jones, P. T., et al., Nature 321:552 (May 1986) constructed and expressed a genomic construct where CDR domains of variable regions from a mouse mono-lonal antibody were used to substitute for the cor-responding domains in a human antibody.
Sun, L.R., et al., Hybridoma 5 suppl. 1 S17 (1986), describes a chimeric human/mouse antibody with potential tumor specificty. The chimeric heavy and light chain genes are genomic constructs and expressed in mammalian cells.
Sahagan et al., J. Immun. 137:1066-1074 (August 1986) describe a chimeric antibody with specificity to a human tumor associated antigen, the genes for which are assembled from genomic sequences.
For a recent review of the field see also Morri-son, S.L., Science 229: 1202-1207 (September 20, 1985) and Oi, V. T., et al., BioTechniques 4:214 (1986).
The oi, et al., paper is relevant as it argues that the production of chimeric antibodies from CDNA
constructs in yeast and/or bacteria is not necessarily advantageous.
See also Commentary on page 835 in Biotechnology 4 (1986).

SUMMARY OF THE INVENTION
The invention provides a genetically engineered chimeric antibody of desired variable region specifi-city and constant region properties, through gene cloning and expression of light and heavy chains. The cloned immunoglobulin gene products can be produced by expression in genetically engineered cells.
The application of oligodeoxyribonucleotide syn-thesis, recombinant DNA cloning, and production of specific immunoglobulin chains in various prokaryotic -lo- 1 3 3 6 8 2 6 and eukaryotic cells provides a means for the large scale production of a chimeric human/mouse monoclonal antibody with specificity to a human B cell surface antigen.
The invention provides cDN~ sequences coding for immunoglobulin chains comprising a constant human region and a variable, non-human, region. The immuno-globulin chains can be either heavy or light.
The invention provides gene sequences coding for immunoglobulin chains comprising a cDNA variable region of the desired specificity. These can be com-bined with genomic constant regions of human origin.
The invention provides sequences as above, present in recombinant DNA molecules in vehicles such as plas-mid vectors, capable of expression in desired prokary-otic or eukaryotic hosts.
The invention provides hosts capable of producing, by culture, the chimeric antibodies and methods of using these hosts.
The invention also provides individual chimeric immunoglobulin chains, as well as complete assembled molecules having human constant regions and variable regions with a human B cell surface antigen speci-ficity, wherein both variable regions have the same binding specificity.
~ mong other immunoglobulin chains and/or molecules provided by the invention are:
(a) a complete functional, immunoglobulin mole-cule comprising:
(i) two identical chimeric heavy chains com-prising a variable region with a human B
cell surface antigen specificity and human constant region and 1 33682~

(ii) two identical all (i.e. non-chimeric) human light chains.
(b) a complete, functional, immunoglobulin mole-cule comprising:
(i) two identical chimeric heavy chains com-prising a variable region as indicated, and a human constant region, and (ii) two identical all (i.e. non-chimeric) non-human light chains.
(c) a monovalent antibody, i.e., a complete, functional immunoglobulin molecule compris-ing:
(i) two identical chimeric heavy chains com-prising a variable region as indicated, and a human constant region, and (ii) two different light chains, only one of which has the same specificity as the variable region of the heavy chains.
The resulting antibody molecule binds only to one end thereof and is therefore incapable of divalent binding.
Genetic sequences, especially cDNA sequences, cod-ing for the aforementioned combinations of chimeric chains or of non-chimeric chains are also provided herein.
The invention also provides for a genetic sequence, especially a cDNA sequence, coding for the variable region of desired specificity of an antibody molecule heavy and/or light chain, operably linked to a sequence coding for a polypeptide different than an immunoglobulin chain (e.g., an enzyme). These sequences can be assembled by the methods of the invention, and expressed to yield mixed-function molecules.

The use of cDNA sequences is particularly advan-tageous over genomic sequences (which contain introns), in that cDNA sequences can be expressed in bacteria or other hosts which lack appropriate RNA
splicing systems.

BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1 shows the DNA rearrangements and the ex-pression of immunoglobulin mu and qamma heavy chain genes. This is a schematic representation of the hu-man heavy chain gene complex (not shown to scale).
Heavy chain variable V region formation occurs through the proper joining of VH, D and JH gene segments.
This generates an active _ gene. A different kind of DNA rearrangement called "class switching" relocates the joined VH~ D and JH region from the vicinity of _ constant C region to that of another heavy chain C
region (switching to qamma is diagrammed here).
FIGURE 2 shows the known nucleotide sequences of human and mouse J regions. Consensus sequences for the J regions are shown below the actual sequences.
The oligonucleotide sequence below the mouse kappa J
region consensus sequence is a Universal Immunoglobu-lin Gene (UIG) oligonucleotide. Note that there are only a few J regions with relatively conserved se-quences, especially near the constant regions, in each immunoglobulin gene locus.
FIGURE 3 shows the nucleotide sequences of the mouse J regions. Shown below are the oligonucleotide primers UIG-H and UIG-K. Note that each contains a restriction enzyme site. They can be used as primers for the synthesis of cDNA complementary to the vari-able region of mRNA, and can also be used to mutagen-ize, in vitro, cloned cDN~.
FIGURE 4 Human Constant Domain Modules. The human C gamma 1 clone, pGMH6, was isolated from the cell line GM2146. The sequence at its JH-CHl junction is shown. Two restriction enzyme sites are useful as joints in recombining the CHl gene with different VH
genes. The ApaI site is 16 nucleotide residues into the CHl coding domain of Human gamma l; and is used in a previous construction of a mouse-human chimeric heavy-chain immunoglobulin. The BstEII site is in the JH region, and is used in the construction described in this application.
The human CK clone, pGML60, is a composite of two cDNA clones, one isolated from GM1500 (pK2-3), the other from GM2146 (pGMLl). The JK-CK junction se-quence shown comes from pK2-3. In vitro mutagenesis using the oligonucleotide, JKHindIII, was carried out to engineer a HindIII site 14 nucleotide residues 5' of the J-C junction. This changes a human GTG codon into a CTT codon.
FIGURE 5 shows the nucleotide sequence of the V
region of the 2H7 VH cDNA clone pH2-11. The sequence was determined by the dideoxytermination method using M13 subclones of gene fragments. Open circles denote amino acid residues confirmed by peptide sequence. A
sequence homologous to DSp 2 in the CDR3 region is underlined. The NcoI site at 5' end was converted to a SalI site by using SalI linkers.
FIGURE 6 shows the nucleotide sequence of the V
region of the 2H7 VK cDNA clone pL2-12. The oligonu-cleotide primer used for site-directed mutagenesis is shown below the JK5 segment. Open circles denote amino acid residues confirmed by peptide sequence.

: -14- 1 336826 FIGURE 7 shows the construction of the light and heavy chain expression plasmids pING2106 (panel a) and pING2101 (panel B). The SalI to BamHI fragment from pING2100 is identical to the SalI to BamHI fragment from pING2012E (see panel C). A linear representation of the circular plasmid pING2012E is shown in panel C.
The 6.6 Kb SalI to BamHI fragment contains sequences from pSV2-neo, pUC12, M8alphaRX12, and pLl. The HindIII site in pSV2-neo was destroyed before assembly of pING2012E by HindIII cleavage, fill-in, and religation.
FIGURE 8 shows the structure of several chimeric 2H7-VH expression plasmids. pING2107 is a qpt version of the light chain plasmid, pING2106. The larger ones are two-gene plasmids. pHL2-11 and pHL2-26 contain both H and L genes, while pLL2-25 contains two L
genes. They were constructed by joining an NdeI
fragment containing either an H or L gene to partially digested (with NdeI) pING2106.
FIGURE 9 shows a summary of the sequence altera-tions made in the construction of the 2H7 chimeric antibody expression plasmids. Residues underlined in the 5' untranslated region are derived from the cloned mouse kappa and heavy-chain genes. Residues circled in the V/C boundary result from mutagenesis operations to engineer restriction enzyme sites in this region.

DESCRIPTION OF THE PREFERRED EMBODIMENTS
INTRODUCTION
Generally, antibodies are composed of two light and two heavy chain molecules. Light and heavy chains are divided into domains of structural and functional homology. The variable domains of both the light (VL) and the heavy (VH) chains determine recognition and specificity. The constant region domains of light (CL) and heavy (CH) chains confer important biological -15- l 3 3 6 8 2 6 properties such as antibody chain association, secre-tion, transplacental mobility, complement binding, and the like.
A complex series of events leads to immunoglobulin gene expression in the antibody producing cells. The V region gene sequences conferring antigen speci-ficity and binding are located in separate germ line gene segments called VH, D and JH; or VL and JL.
These gene segments are joined by DNA rearrangements to form the complete V regions expressed in heavy and light chains respectively (Figure 1). The rearranged, joined (VL-JL and VH-D- JH) V segments then encode the complete variable regions or antigen binding domains of light and heavy chains, respectively.

DEFINITIONS
Certain terms and phrases are used throughout the specification and claims. The following definitions are provided for purposes of clarity and consistency.
1. Expression vector - a plasmid DNA containing necessary regulatory signals for the synthesis of mRNA
derived from any gene sequence, inserted into the vec-tor.

2. Module vector - a plasmid DNA containing a constant or variable region gene module.

3. Expression plasmid - an expression vector that contains an inserted gene, such as a chimeric immuno-globulin gene.

4. Gene cloning - synthesis of a gene, insertion into DNA vectors, identification by hybridization, sequence analysis and the like.

5. Transfection - the transfer of DNA into mam-malian cells.

GBNETIC PROCESSES AND PRODUCTS
The invention provides a novel approach for the cloning and production of a human/mouse chimeric anti-body with specificity to a human B cell surface anti-gen. The antigen is a polypeptide or comprises a polypeptide bound by the 2H7 monoclonal antibody des-cribed in Clark et al. Proc. Natl. Acad. Sci., U.S.A.
82:1766-1770 (1985). This antigen is a phosphoprotein designated (Bp35(CD20)) and is only expressed on cells of the B cell lineage. Murine monoclonal antibodies to this antigen have been made before and are described in Clark et al., supra; see also Stashenko, P., et al., J. Immunol. 125:1678-1685 (1980).
The method of production combines five elements:
(1) Isolation of messenger RNA (mRNA) from the mouse hybridoma line producing the monoclonal antibody, cloning and cDNA production therefrom;
(2) Preparation of Universal Immunoglobulin Gene (UIG) oligonucleotides, useful as primers and/or probes for cloning of the variable region gene segments in the light and heavy chain mRNA from the hybridoma cell line, and cDNA production therefrom;
(3) Preparation of constant region gene segment modules by cDNA preparation and cloning, or genomic gene preparation and cloning;
(4) Construction of complete heavy or light chain coding sequences by linkage of the cloned specific immunoglobulin variable region gene segments of part (2) above to cloned human constant region gene segment modules;
(S) Expression and production of light and heavy chains in selected hosts, including prokary-otic and eukaryotic cells, either in separate fermentations followed by assembly of anti-body molecules in vitro, or through produc-tion of both chains in the same cell.
One common feature of all immunoglobulin light and heavy chain genes and the encoded messenger RNAs is the so-called J region (i.e. joining region, see Figure 1). Heavy and light chain J regions have dif-ferent sequences, but a high degree of sequence hom-ology exists (greater than 80%) especially near the constant region, within the heavy JH regions or the kappa light chain J regions. This homology is ex-ploited in this invention and consensus sequences of light and heavy chain J regions were used to design oligonucleotides (designated herein as UIGs) for use as primers or probes for cloning immunoglobulin light or heavy chain mRNAs or genes (Figure 3). Depending on the sequence of a particular UIG, it may be capable of hybridizing to all immunoglobulin mRNAs or a speci-fic one containing a particular J sequence. Another utility of a particular UIG probe may be hybridization to light chain or heavy chain mRNAs of a specific con-stant region, such as UIG-MJK which detects all mouse JK-containing sequences (Figure 2).
UIG design can also include a sequence to intro-duce a restriction enzyme site into the cDNA copy of an immunoglobulin gene (see Figure 3). The invention may, for example, utilize chemical gene synthesis to generate the UIG probes for the cloning and modifi-cation of V regions from immunoglobulin mRNA. On the other hand, oligonucleotides can be synthesized to recognize individually, the less conserved 5'-region of the J regions as a diagnostic aid in identifying the particular J region present in the immunoglobulin mRNA.
A multi-step procedure is utilized for generating complete V+C region cDNA clones from the hybridoma cell light and heavy chain mRNAs. First, the comple-mentary strand of oligodT-primed cDNA is synthesized, and this double-stranded cDNA is cloned in appropriate cDNA cloning vectors such as pBR322 (Gubler and Hof-fman, Gene, 25: 263 tl983)). Clones are screened by hybridization with UIG oligonucleotide probes. Posi-tive heavy and light chain clones identified by this screening procedure are mapped and sequenced to select those containing V region and leader coding sequences.
In vitro mutagenesis including, for example, the use of UIG oligonucleotides, is then used to engineer de-sired restriction enzyme cleavage sites. We used this approach for the chimeric 2H7 light chain.
An expedient method is to use synthetic ~IG
oligonucleotides as primers for the synthesis of cDNA.
This method has the advantage of simultaneously in-troducing a desired restriction enzyme site, such as BstEII (Figure 3) into a V region cDNA clone. We used this approach for the chimeric 2H7 heavy chain.
Second, cDNA constant region module vectors are prepared from human cells. These cDNA clones are modified, when necessary, by site-directed mutagenesis to place a restriction site at the analogous position in the human sequence or at another desired location near a boundary of the constant region. An alterna-tive method utilizes genomic C region clones as the source for C region module vectors.
Third, cloned V region segments generated as above are excised and ligated to light or heavy chain C
region module vectors. For example, one can clone the complete human kaPPa light chain C region and the com-plete human qammal C region. In addition, one can modify the human qammal region to introduce a termina-tion codon and thereby obtain a gene sequence which encodes the heavy chain portion of an Fab molecule.
The coding sequences having operationally linked V
and C regions are then transferred into appropriate expression vehicles for expression in appropriate hosts, prokaryotic or eukaryotic. Operationally link-ed means in-frame joining of coding sequences to de-rive a continuously translatable gene sequence with-out alterations or interruptions of the triplet read-ing frame.
One particular advantage of using cDNA genetic sequences in the present invention is the fact that they code continuously for immunoglobulin chains, either heavy or light. By "continuously" is meant that the sequences do not contain introns (i.e. are not genomic sequences, but rather, since derived from mRNA by reverse transcription, are sequences of con-tiguous exons). This characteristic of the cDNA se-quences provided by the invention allows them to be expressible in prokaryotic hosts, such as bacteria, or in lower eukaryotic hosts, such as yeast.

Another advantage of using cDNA cloning method is the ease and simplicity of obtaining variable region gene modules.
The terms "constant" and "variable" are used func-tionally to denote those regions of the immunoglobulin chain, either heavy or light chain, which code for properties and features possessed by the variable and constant regions in natural non-chimeric antibodies.
As noted, it is not necessary for the complete coding region for variable or constant regions to be present, as long as a functionally operating region is present and available.
Expression vehicles include plasmids or other vec-tors. Preferred among these are vehicles carrying a functionally complete human constant heavy or light chain sequence having appropriate restriction sites engineered so that any variable heavy or light chain sequence with appropriate cohesive ends can be easily inserted thereinto. Human constant heavy or light chain sequence-containing vehicles are thus an impor-tant embodiment of the invention. These vehicles can be used as intermediates for the expression of any desired complete heavy or light chain in any appro-priate host.
One preferred host is yeast. Yeast provides sub-stantial advantages for the production of immunoglo-bulin light and heavy chains. Yeasts carry out post-translational peptide modifications including glycosy-lation. A number of recombinant DNA strategies now exist which utilize strong promoter sequences and high copy number plasmids which can be used for overt pro-duction of the desired proteins in yeast. Yeast re-cognizes leader sequences on cloned mammalian gene products and secretes peptides bearing leader se-quences (i.e. prepeptides) (Hitzman, et al., 11th International Conference on Yeast, Genetics and Mole-cular Biology, Montpelier, France, September 13-17, 1982).
Yeast gene expression systems can be routinely evaluated for the level of heavy and light chain pro-duction, protein stability, and secretion. Any of a series of yeast gene expression systems incorporating promoter and termination elements from the actively expressed genes coding for glycolytic enzymes produced in large quantities when yeasts are grown in mediums rich in glucose can be utilized. Known glycolytic genes can also provide very efficient transcription control signals. For example, the promoter and term-inator signals of the iso-l-cytochrome C tCYC-l) gene can be utilized.
The following approach can be taken to develop and evaluate optimal expression plasmids for the expression of cloned immunoglobulin cDNAs in yeast.
(1) The cloned immunoglobulin DNA linking V and C
regions is attached to different transcrip-tion promoters and terminator DNA fragments;
(2) The chimeric genes are placed on yeast plas-mids (see, for example, Broach, J.R. in Methods in Enzymology - Vol. 101:307 ed. Wu, R. et al., 1983));
(3) Additional genetic units such as a yeast leader peptide may be included on immunoglob-ulin DNA constructs to obtain antibody secre-tion.

(4) A portion of the sequence, frequently the first 6 to 20 codons of the gene sequence may be modified to represent preferred yeast codon usage.
(5) The chimeric genes are placed on plasmids used for integration into yeast chromosomes.
The following approaches can be taken to simultan-eously express both light and heavy chain genes in yeast.
(1) The light and heavy chain genes are each at-tached to a yeast promoter and a terminator sequence and placed on the same plasmid.
This plasmid can be designed for either auto-nomous replication in yeast or integration at specific sites in the yeast chromosome.
(2) The light and heavy chain genes are each at-tached to a yeast promoter and terminator sequence on separate plasmids containing dif-ferent selectable markers. For example, the light chain gene can be placed on a plasmid containing the trpl gene as a selectable marker, while the heavy chain gene can be placed on a plasmid containing ura3 as a selectable marker. The plasmids can be designed for either autonomous replication in yeast or integration at specific sites in yeast chromosomes. A yeast strain defective for both selectable markers is either simultaneously or sequentially transformed with the plasmid containing the light chain gene and with the plasmid containing the heavy chain gene.

(3) The light and heavy chain genes are each at-tached to a yeast promoter and terminator sequence on separate plasmids each containing different selectable markers as described in (2) above. A yeast mating type "a" strain defective in the selectable markers found on the light and heavy chain expression plasmids (trpl and ura3 in the above example) is transformed with the plasmid containing the light chain gene by selection for one of the two selectable markers (trpl in the above example). A yeast mating type "alpha" strain defective in the same selectable markers as the "a" strain (i.e. trpl and ura3 as exam-ples) is transformed with a plasmid contain-ing the heavy chain gene by selection for the alternate selectable marker (i.e. ura3 in the above example). The "a" strain containing the light chain plasmid (phenotype: Trp Ura in the above example) and the strain containing the heavy chain plasmid (pheno-type: Trp Ura in the above example) are mated and diploids are selected which are prototrophic for both of the above selectable markers (Trp+ Ura in the above example).
Among bacterial hosts which may be utilized as transformation hosts, E. coli R12 strain 294 (ATCC
31446) is particularly useful. Other microbial strains which may be used include E. coli X1776 (ATCC
31537). The aforementioned strains, as well as E.
coli W3110 (ATCC 27325) and other enterobacteria such as Salmonella typhimurium or Serratia marcescens, and various Pseudomonas species may be used.

In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with a host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as specific genes which are capable of providing phenotypic selection in trans-formed cells. For example, E. coli is readily trans-formed using pBR322, a plasmid derived from an E. coli species (Bolivar, et al., Gene, 2: 95 (1977)). pBR322 contains genes for ampicillin and tetracycline resis-tance, and thus provides easy means for identifying transformed cells. The pBR322 plasmid or other micro-bial plasmids must also contain, or be modified to contain, promoters which can be used by the microbial organism for expression of its own proteins. Those promoters most commonly used in recombinant DNA con-struction include the beta-lactamase (penicillinase) and lactose (beta-galactosidase) promoter systems (Chang et al., Nature, 275: 615 (1978); Itakura et al., Science, 198:1056 (1977)); and tryptophan pro-moter systems (Goeddel et al., Nucleic Acids Research, 8: 4057 (1980); EPO Publication No. 0036776). While these are the most commonly used, other microbial pro-moters have been discovered and utilized.
For example, a genetic construct for any heavy or light chimeric immunoglobulin chain can be placed un-der the control of the leftward promoter of bacteri-ophage lambda (PL). This promoter is one of the strongest known promoters which can be controlled.
Control is exerted by the lambda repressor, and adja-cent.restriction sites are known.

The expression of the immunoglobulin chain se-quence can also be placed under control of other regu-latory sequences which may be "homologous" to the organism in its untransformed state. For example, lactose dependent E. coli chromosomal DNA comprises a lactose or lac operon which mediates lactose digestion by elaborating the enzyme beta-galactosidase. The lac control elements may be obtained from bacteriophage lambda pLAC5, which is infective for E. coli. The lac promoter-operator system can be induced by IPTG.
Other promoter/operator systems or portions there-of can be employed as well. For example, arabinose, colicine El, galactose, alkaline phosphatase, trypto-phan, xylose, tac, and the like can be used.
Other preferred hosts are mammalian cells, grown in vitro in tissue culture, or in vivo in animals.
Mammalian cells provide post-translational modifica-tions to immunoglobulin protein molecules including leader peptide removal, correct folding and assembly of heavy and light chains, proper glycosylation at correct sites, and secretion of functional antibody protein.
Mammalian cells which may be useful as hosts for the production of antibody proteins include cells of lymphoid origin, such as the hybridoma Sp2/0-Agl4 (ATCC CRL 1581) or the myleoma P3X63Ag8 (ATCC TIB 9), and its derivatives. Others include cells of fibro-blast origin, such as Vero (ATCC CRL 81) or CHO- Kl (ATCC CRL 61).
Several possible vector systems are available for the expression of cloned heavy chain and light chain genes in mammalian cells. One class of vectors re-lies upon the integration of the desired gene se-quences into the host cell genome. Cells which have stably integrated DNA can be selected by simultaneous-ly introducing drug resistance genes such as E. coli qpt (Mulligan, R. C. and Berg, P., Proc. Natl. Acad.
Sci., USA, 78: 2072 (1981)) or Tn5 neo (Southern, P.
J. and Berg, P., J. Mol. Appl. Genet., 1: 327 (1982)).
The selectable marker gene can be either linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection (Wigler, M. et al., Cell, 16: 77 (1979)). A second class of vectors uti-lizes DNA elements which confer autonomously replicat-ing capabilities to an extrachromosomal plasmid.
These vectors can be derived from animal viruses, such as bovine papillomavirus (Sarver, N. et al., Proc.
Natl. Acad. Sci., USA, 79: 7147 (1982)), polyoma virus (Deans, R. J. et al., Proc. Natl. Acad. Sci., USA, 81:
1292 (1984)), or SV40 virus (Lusky, M. and Botchan, M., Nature, 293: 79 (1981)).
Since an immunoglobulin cDN~ is comprised only of sequences representing the mature mRNA encoding an antibody protein additional gene expression elements regulating transcription of the gene and processing of the RNA are required for the synthesis of immunoglobu-lin mRNA. These elements may include splice signals, transcription promoters, including inducible pro-moters, enhancers, and termination signals. cDNA
expression vectors incorporating such elements include those described by Okayama, H. and Berg, P., Mol. Cell Biol., 3: 280 (1983); Cepko, C. L. et al., Cell, 37:
1053 (1984); and Kaufman, R. J., Proc. Natl. Acad.
Sci., USA, 82: 689 (1985).

An additional advantage of mammalian cells as hosts is their ability to express chimeric immunoglob-ulin genes which are derived from genomic sequences.
Thus, mammalian cells may express chimeric immunoglob-ulin genes which are comprised of a variable region cDNA module plus a constant region which is composed in whole or in part of genomic sequences. Several human constant region genomic clones have been des-cribed (Ellison, J. W. et al., Nucl. Acids Res., 10:
4071 (1982), or Max, E. et al., Cell, 29: 691 (1982)).
The use of such genomic sequences may be convenient for the simultaneous introduction of immunoglobulin enhancers, splice signals, and transcription termina-tion signals along with the constant region gene seg-ment.
Different approaches can be followed to obtain complete H2L2 antibodies.
First, one can separately express the light and heavy chains followed by in vitro assembly of purified light and heavy chains into complete H2L2 IgG anti-bodies. The assembly pathways used for generation of complete H2L2 IgG molecules in cells have been exten-sively studied (see, for example, Scharff, M., Harvey Lectures, 69: 125 (1974)). In vitro reaction para-meters for the formation of IgG antibodies from re-duced isolated light and heavy chains have been defin-ed by Beychok, S., Cells of Immunoglobulin Synthesis, Academic Press, New York, page 69, 1979.
Second, it is possible to co-express light and heavy chains in the same cells to achieve intracellu-lar association and linkage of heavy and light chains into complete H2L2 IgG antibodies. The co-expression can occur by using either the same or different plas-mids in the same host.

POLYPEPTI DE PRODUCTS
The invention provides "chimeric n immunoglobulin chains, either heavy or light. A chimeric chain con-tains a constant region substantially similar to that present in a natural human immunoglobulin, and a variable region having the desired antigenic specifi-city of the invention, i.e., to the specified human B
cell surface antigen.
The invention also provides immunoglobulin mole-cules having heavy and light chains associated so that the overall molecule exhibits any desired binding and recognition properties. Various types of immunoglobu-lin molecules are provided: monovalent, divalent, molecules with chimeric heavy chains and non-chimeric light chains, or molecules with the invention's vari-able binding domains attached to moieties carrying desired functions.
Antibodies having chimeric heavy chains of the same or different variable region binding specificity and non-chimeric (i.e., all human or all non-human) light chains, can be prepared by appropriate associa-tion of the needed polypeptide chains. These chains are individually prepared by the modular assembly methods of the invention.

USES
The antibodies of the invention having human con-stant region can be utilized for passive immunization, especially in humans, without negative immune reac-tions such as serum sickness or anaphylactic shock.
The antibodies can, of course, also be utilized in prior art immunodiagnostic assays and kits in detect-ably labelled form (e.g., enzymes, 125I, 14C, fluor-escent labels, etc.), or in immunobilized form (on polymeric tubes, beads, etc.), in labelled form for in vivo imaging, wherein the label can be a radioactive emitter, or an NMR contrasting agent such as a car-bon-13 nucleus, or an X-ray contrasting agent, such as a heavy metal nucleus. The antibodies can also be used for in vitro localization of the antigen by appropri-ate labelling.
The antibodies can be used for therapeutic pur-poses, by themselves, in complement mediated lysis, or coupled to toxins or therapeutic moieties, such as ricin, etc.
Mixed antibody-enzyme molecules can be used for immunodiagnostic methods, such as ELISA. Mixed anti-body-peptide effector conjugates can be used for tar-geted delivery of the effector moiety with a high de-gree of efficacy and specificity.
Specifically, the chimeric antibodies of this in-vention can be used for any and all uses in which the murine 2H7 monoclonal antibody can be used, with the obvious advantage that the chimeric ones are more com-patible with the human body.
Having now generally described the invention, the same will be further understood by reference to cer-tain specific examples which are included herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.

~30- 1 336826 EXPERIMENTAL
Materials and Methods Tissue Culture Cell Lines The human cell lines GM2146 and GM1500 were ob-tained from the Ruman Mutant Cell Repository (Camden, New Jersey) and cultured in RPMI1640 plus 10% fetal bovine serum (M. A. Bioproducts). The cell line Sp2/0 was obtained from the American Type Culture Col-lection and grown in Dulbecco's Modified Eagle Medium (DMEM) plus 4.5 g/l glucose (M. A. Bioproducts) plus 10% fetal bovine serum (Hyclone, Sterile Systems, Logan, Utah). Media were supplemented with penicil-lin/streptomycin (Irvine Scientific, Irvine, Califor-nia).
Recombinant Plasmid and Bacteriophaqe DNAs The plasmids pBR322, pLl and pUC12 were purchased from Pharmacia P-L Biochemicals (Milwaukee, Wiscon-sin). The plasmids pSV2-neo and pSV2-qPt were obtain-ed from BRL (Gaithersburg, Maryland), and are avail-able from the American Type Culture Collection (Rock-ville, Maryland). pHu-qamma-l is a subclone of the 8.3 Kb H dIII to BamHI fragment of the human IgGl chromosomal gene. An isolation method for of the human IgGl chromosomal gene is described by Ellison, J. W. et al., Nucl. Acids Res., 10: 4071 (1982).
M8alphaRX12 contains the 0.7 Rb XbaI to EcoRI fragment containing the mouse heavy chain enhancer from the J-C
intron region of the M603 chromosomal gene (Davis, M.
et al., Nature, 283:733, 1979) inserted into M13mplO.
DNA manipulations involving purification of plasmid DNA by buoyant density centrifugation, restriction endonuclease digestion, purification of DNA fragments * Trade-mark , ..i , . *~,~

by agarose gel electrophoresis, ligation and trans-formation of E. coli were as described by Maniatis, T.
et al., Molecular Cloning: A Laboratory Manual, (1982) or other procedures. Restriction endonucleases and other DNA/RNA modifying enzymes were purchased from Boehringer-Mannheim (Indianapolis, Indiana), BRL, New England Biolabs (Beverly, Massachusetts) and Pharmacia P-L.
Oligonucleotide Preparation Oligonucleotides were either synthesized by the triester method of Ito et al. (Nucl. Acids Res., 10:
1755 (1982)), or were purchased from ELESEN, Los Angeles, California. Tritylated, deb-locked oligonu-cleotides were purified on Sephadex-G50, followed by reverse-phase HPLC with a 0-25% gradient of acetoni-trile in lOmM triethylamine-acetic acid, pH 7.2, on a C18 Bondapak column (Waters Associates). Detrityla-tion was in 80% acetic acid for 30 min., followed by evaporation thrice. Oligonucleotides were labeled with [gamma-32P]ATP by T4 polynucleotide kinase.
RNA Preparation and Analysis Total cellular RNA was prepared from tissue cul-ture cells by the method of Auffray, C. and Rougeon, F. (Eur. J. Biochem., 107: 303 (1980)) or Chirgwin, J.
M. et al. (Biochemistry, 18: 5294 (1979)). Preparat-ion of poly(A)+ RNA, methyl-mercury agarose gel elec-trophoresis, and ~Northern" transfer to nitrocellulose were as described by Maniatis, T. et al., supra.
Total cellular RNA or poly(A)+ RNA was directly bound to nitrocellulose by first treating the RNA with for-maldehyde (White, B. A. and Bancroft, F. C., J. Biol.
Chem., 257: 8569 (1982)). Hybridization to filterbound * ~rade-mark RNA was with nick-translated DNA fragments using con-ditions described by Margulies, D. H. et al. (Nature, 295: 168 (1982)) or with 32P-labelled oligonucleotide using 4xSSC, lOX Denhardt's, 100 ug/ml salmon sperm DNA at 37C overnight, followed by washing in 4xSSC at 37C.
cDNA Preparation and Cloning Oligo-dT primed cDNA libraries were prepared from poly(A)+ RNA from GM1500 and GM2146 cells by the me-thods of Land, H. et al. (Nucl. Acids Res., 9: 2251 (1981)) and Gubler, V. and Hoffman, B. J., Gene, 25:
263 (1983), respectively. The cDNA libraries were screened by hybridization (Maniatis, T., supra) with 32P-labelled oligonucleotides using the procedure of de Lange et al. (Cell, 34: 891 (1983)), or with nick-translated DNA fragments.
Oligonucleotide Primer Extension and Cloning Poly(A) RNA (20 ug) was mixed with 1.2 ug primer in 40 ul of 64mM KCl. After denaturation at 90C for 5 min. and then chilling in ice, 3 units Human Placen-tal Ribonuclease Inhibitor (BRL) was added in 3 ul of lM Tris-HCl, pH 8.3. The oligonucleotide was annealed to the RNA at 42C for 15 minutes, then 12 ul of .05M
DTT, .05M MgC12, and 1 mM each of dATP, dTTP, dCTP, and dGTP was added. 2 ul of alpha- P-dATP (400 Ci/mmol, New England Nuclear) was added, followed by 3 ul of AMV reverse transcriptase (19 units/ul, Life Sciences).
After incubation at 42C for 105 min., 2 ul 0.5 M
EDTA and 50 ul lOmM Tris, lmM EDTA, pH 7.6 were added.
Unincorporated nucleotides were removed by Sephadex G-50 spin column chromatography, and the RNA-DNA hy-*Trade Mark ~33~ 1 3 3 6 8 2 6 brid was extracted with phenol, then with chloroform,and precipitated with ethanol. Second strand synthe-sis, homopolymer tailing with dGTP or dCTP, and inser-tion into homopolymer tailed vectors was as described by Gubler and Hoffman, supra.
Site-Directed Mutagenesis Single stranded M13 subclone DNA (1 ug) was com-bined with 20 ng oligonucleotide primer in 12.5 ul of Hin buffer (7 mM Tris-HCl, pH 7.6, 7 mM MgC12, 50 mM
NaCl). After heating to 95C in a sealed tube, the primer was annealed to the template by slowly cooling from 70C to 37 C for 90 minutes. 2 ul dNTPs (1 mM
each), 1 ul 32P-dATP (10 uCi), 1 ul ~TT (0.1 M) and 0.4 ul Rlenow DNA PolI (2u, Boehringer Mannheim) were added and chains extended at 37C for 30 minutes. To this was added 1 ul (10 ng) M13 reverse primer (New England Biolabs), and the heating/annealing and chain extension steps were repeated. The reaction was stopped with 2 ul of 0.SM EDTA, pH 8, plus 80 ul of 10 mM Tris-HCl, pH 7.6, 1 mM EDTA. The products were phenol extracted and purified by Sephadex G-50 spun column chromatography and ethanol precipitated prior to restriction enzyme digestion and ligation to the appropriate vector.
Transfection of Myeloma Tissue Culture Cells The electroporation method of Potter, H. et al.
(Proc. Natl. Acad. Sci., USA, 81: 7161 (1984)) was used. After transfection, cells were allowed to re-cover in complete DMEM for 48-72 hours, then were seeded at 10,000 to 50,000 cells per well in 96-well culture plates in the presence of selective medium.
G418 (GIBCO) selection was at 0.8 mg/ml, and myco-*Trade Mark .... ., I
, . . .

-34~ 1 3 3 6 8 2 6 phenolic acid (Calbiochem) was at 6 ug/ml plus 0.25 mg/ml xanthine.
Assays for Immunoglobulin Synthesis and Secretion Secreted immunoglobulin was measured directly from tissue culture cell supernatants. Cytoplasmic protein extract was prepared by vortexing 106 cells in 160 ul of 1% NP40, 0.15 M NaCl, 10 mM Tris, 1 mM EDTA, pH 7.6 and leaving the lysate at 0C, 15 minutes, followed by centrifugation at 10,000 x ~ to remove insoluble debris.
A double antibody sandwich ~LISA (Voller, A. et _1., in Manual of Clinical Immunology, 2nd Ed., Eds.
Rose, N. and Friedman, H., pp. 359-371, 1980) using affinity purified antisera was used to detect specific immunoglobulins. For detection of human IgG, the plate-bound antiserum is goat anti-human IgG (KPL, Gaithersburg, Maryland) at 1/1000 dilution, while the peroxidase-bound antiserum is goat anti-human IgG (KPL
or Tago, Burlingame) at 1/4000 dilution. For detec-tion of human immunoglobulin kappa, the plate-bound antiserum is goat anti-human kappa (Tago) at 1/500 dilution, while the peroxidase-bound antiserum is goat anti-human kappa tCappel) at 1/1000 dilution.

A Chimeric Mouse-Human Immunoglobulin with Specificity for a Human B Cell Surface Antigen (1) Antibody 2H7.
The 2H7 mouse monoclonal antibody (gamma 2b, kappa) recognizes a human B-cell surface antigen, (Bp35(CD20)) Clark, E.A., et al., Proc. Natl. Acad.
Sci., U.S.A. 82:1766 (1985)). The (Bp35(CD20)) ~35~ 1 3 3 6 8 2 6 molecules presumably play a role in B-cell activation.
The antibody 2H7 does not react with stem cells which are progenitors of B cells epithelial, mesenchymal and fibroblastic cells of other organs.
(2) Identification of J Sequences in the Immuno-globulin mRNA of 2H7.
Frozen cells were thawed on ice for 10 minutes and then at room temperature. The suspension was diluted with 15 ml PBS and the cells were centrifuged down.
They were resuspended, after washes in PBS, in 16 ml 3M LiCl, 6M urea and disrupted in a polytron shear.
The preparation of mR~A and the selection of the poly(A+) fraction were carried out according to Auf-fray, C. and Rougeon, F., Eur. J. Biochem. 107:303, 1980.
The poly (A+) RNA from 2H7 was hybridized individually with labeled JHl, JH2, JH3 and JH4 oligo-nucleotides under conditions described by Nobrega et al. Anal. Biochem 131:141, 1983). The products were then subjected to electrophoresis in a 1.7% agarose-TBE gel. The gel was fixed in 10% TCA, blotted dry and exposed for autoradiography. The result showed that the 2H7 VH contains JHl, JH2, orJH4 but not JH3 sequences.
For the analysis of the VK mRNA, the dot-blot method of White and Bancroft J. Biol. Chem. 257:8569, (1982) was used. Poly (A+) RNA was immobilized on nitrocellulose filters and was hybridized to labeled probe-oligonucleotides at 40 in 4xSSC. These experi-ments show that 2H7 contains JK5 sequences.
(3) V Region cDNA Clones.
A library primed by oligo (dT) on 2H7 poly (A+) RNA was screened for kappa clones with a mouse CK

region probe. From the 2H7 library, several clones were isolated. A second screen with a 5' JK5 specific probe identified the 2H7 (JK5) light-chain clones.
Heavy chain clones of 2H7 were generated by priming the poly(A+) RN~ with the UIGH(BstEII) oligonucleotide (see Figure 3), and identified by screening with the UIGH(BstEII) oligonucleotide.
The heavy and light chain genes or gene fragments from the VH and VK cDNA clones pH2-11 and pL2-12 were inserted into M13 bacteriophage vectors for nucleotide sequence analysis. The complete nucleotide sequences of the variable region of these clones were determined (FIGURES 5 and 6) by the dideoxy chain termination method. These sequences predict V region amino acid compositions that agree well with the observed compo-sitions, and predict peptide sequences which have been verified by direct amino acid sequencing of portions of the V regions.
The nucleotide sequences of the cDNA clones show that they are immunoglobulin V region clones as they contain amino acid residues diagnostic of V domains (Kabat et al., Sequences of Proteins of Immunological Interest; U.S. Dept of HHS, 1983).
The 2H7 VH has the JHl sequence. The 2H7 VL is from the VK-KpnI family (Nishi et al. Proc. Nat. Acd.
Sci. USA 82:6399, 1985), and uses JK5. The cloned 2H7 VL predicts an amino acid sequence which was confirmed by amino acid sequencing of peptides from the 2H7 light chain corresponding to residues 81-100. The cloned 2H7 VH predicts an amino acid sequence con-firmed also by peptide sequencing, namely residues 1-12.

(4) In Vitro Mutagenesis to Enqineer Restriction Enzyme Sites in the J Region for Joining to a Human C-Module, and to Remove Oligo (dC) Sequences 5' to the V Modules.
For the 2H7 VK, the J-region mutagenesis primer J HindIII, as shown in FIGURE 6, was utilized. A
K
human CK module derived from a cDNA clone was also mutagenized to contain the HindIII sequence (see Figure 4). The mutagenesis reaction was performed on M13 subclones of these genes. The frequency of mutant clones ranged from 0.5 to 1% of the plaques obtained.
It had been previously observed that the oligo (dC) sequence upstream of the AUG codon in a VH chi-meric gene interferes with proper splicing in one par-ticular gene construct. It was estimated that per-haps as much as 70% of the RNA transcripts had under-gone the mis-splicing, wherein a cryptic 3' splice acceptor in the leader sequence was used. Therefore the oligo ~dC) sequence upstream of the initiator AUG
was removed in all of the clones.
In one approach, an oligonucleotide was used which contains a SalI restriction site to mutagenize the 2H7 VK clone. The primer used for this oligonucleotide-directed mutagenesis is a 22-mer which introduces a SalI site between the oligo (dC) and the initiator met codon (FIGURE 6).
In a different approach, a convenient NcoI site was utilized to delete the 5' untranslated region and oligo (dC) of the 2H7 VH clone (see Figure 5).
The human C gamma 1 gene module is a cDNA derived from GM2146 cells (Human Genetic Mutant Cell Reposi-tory, Newark, New Jersey). This C qamma 1 gene module was previously combined with a mouse VH gene module to form the chimeric expression plasmid pING2012E (Figure 7C).
(5) Chimeric 2H7 Expression Plasmids.
A 2H7 chimeric heavy chain expression plasmid was derived from the replacement of the VH module of pING2012E with the VH cDNA modules to give the expres-sion plasmid pING2101 (FIGURE 7B). This plasmid directs the synthesis of chimeric 2H7 heavy chain when transfected into mammalian cells.
For the 2H7 light chain chimeric gene, the SalI to HindIII fragment of the mouse VK module was joined to the human CK module by the procedure outlined in FIGURE 7A, forming pING2106. Replacement of the neo sequence with the E. coli gpt gene derived from pSV2-gpt resulted in pING2107, which expresses 2H7 chimeric light chain and confers mycophenolic acid resistance when transfected into mammalian cells.
The inclusion of both heavy and light chain chi-meric genes in the same plasmid allows for the intro-duction into transfected cells of a 1:1 gene ratio of heavy and light chain genes leading to a balanced gene dosage. This may improve expression and decrease man-ipulations of transfected cells for optimal chimeric antibody expression. For this purpose, the DNA frag-ments derived from the chimeric heavy and light chain genes of pING2101 and pING2106 were combined into the expression plasmids pHL2-11 and pHL2-26 (FIGURE 8).
The pHL2-11 and pHL2-26 plasmids each contain a selectable neo marker and separate transcription units for each chimeric gene, each gene including a mouse heavy chain enhancer.
The modifications and V-C joint regions of the 2H7 chimeric genes are summarized in FIGURE 9.

(6) Stable Transfection of Mouse Lymphoid Cells for the Production of Chimeric Antibody.
Electroporation was used (Potter et al. supra;
Toneguzzo et al. Mol. Cell Biol. 6:703 1986) for the introduction of 2H7 chimeric expression plasmid DNA
into mouse Sp2/0 cells. The electroporation technique gave a transfection frequency of 10 4 x 10 5 for the Sp2/0 cells.
The expression plasmids, pING2101 and pING2106, were digested with NdeI; and the DNA was introduced into Sp2/0 cells by electroporation. Transformant lD6 was obtained which secretes chimeric 2H7 antibody.
Antibody isolated from this cell line was used for the functional assays done to characterize the chimeric antibody. We have also obtained transformants from experiments using the two-gene plasmids.

(7) Purification of Chimeric 2H7 Antibody Secreted in Tissue Culture.
a. lD6 (Sp2/O.pING2101/pING2106.1D6) cells were grown in culture medium [DMEM (Gibco #320-1965), supplemented with 10~ Fetal Bovine Serum (Hyclone #A-llll-D), lOmM HEPES, lx Glutamine-Pen-Strep (Irvine Scientific #9316) to 1 x 106 cell/ml.
b. The cells were then centrifuged at 400xg and resuspended in serum-free culture medium at 2 x 106 cell/ml for 18-24 hr.
c. The medium was centrifuged at 4000 RPM
in a JS-4.2 rotor (3000xg) for 15 min.
d. 1.6 liter of supernatant was then fil-tered through a 0.45 micron filter and then concen-trated over a YM30 (Amicon Corp.) filter to 25ml.

e. The conductance of the concentrated supernatant was adjusted to 5.7-5.6 mS/cm CDM 80 radiometer and the pH was adjusted to 8Ø
f. The supernatant was centrifuged at 2000xg, S min., and then loaded onto a 40 ml DEAE
column, which was preequilibrated with lOmM sodium phosphate, pH8Ø
g. The flow through fraction was collected and loaded onto a lml protein A-Sepharose (Sigma) column preequilibrated with lOmM sodium phosphate, pH8Ø
h. The column was washed first with 6ml lOmM sodium phosphate buffer pH 8.0, followed by 8ml O.lM sodium citrate pH 3.5, then by 6ml O.lM citric acid (pH 2.2). Fractions of 0.5ml were collected in tubes containing 50ul 2M Tris base (Sigma).
i. The bulk of the IgG was in the pH 3.5 elution and was pooled and concentrated over Centricon 30 (Amicon Corp.) to approximately .06ml.
j. The buffer was changed to PBS (lOmM so-dium phosphate pH 7.4, 0.15M NaCl) in Centricon 30 by repeated diluting with PBS and reconcentrating.
k. The IgG solution was then adjusted to O.lOml and bovine serum albumin (Fraction V, U.S. Bio-chemicals) was added to 1.0% as a stabilizing reagent.

(8) Chimeric 2H7 Antibody, Like the Mouse 2H7 Antibody, Specifically Binds to Human B Cells.
First, the samples were tested with a binding as-say, in which cells of both an 2H7 antigen-positive and an 2H7 antigen-negative cell line were incubated with standard mouse monoclonal antibody 2H7 with chim-eric 2H7 antibody derived from the cell culture super-., ~,, natants, followed by a second reagent, fluorescein-isothiocyanate (FITC)-conjugated goat antibodies to human (or mouse, for the standard) immunoglobulin.
Binding Assays. Cells from a human B cell line, T51, were used. Cells from human colon carcinoma line C3347 were used as a negative control, since they, according to previous testing, do not express detectable amounts of the 2H7 antigen. The target cells were first incubated for 30 min at 4C with either the chimeric 2H7 or with mouse 2H7 standard, which had been purified from mouse ascites. This was followed by incubation with a second, FITC-labelled, reagent, which for the chimeric antibody was goat-anti-human immunoglobulin, obtained from TAGO (Bur-lingame, CA), and used at a dilution of 1:50. For the mouse standard, it was goat-anti-mouse immunoglobulin, also obtained from TAGO and used at a dilution of 1:50. Antibody binding to the cell surface was deter-mined using a Coulter Model EPIC-C cell sorter.
As shown in Table I, both the chimeric and the mouse standard 2H7 bound significantly, and to approximately the same extent, to the positive T51 line. They did not bind above background to the 2H7 negative C-3347 line.
Functional Assays.
In previous studies, antibody 2H7 was tested for antibody-dependent cellular cytotoxicity (ADCC) measured by its ability to lyse 51Cr-labelled human B
lymphoma cells in the presence of human peripheral blood leukocytes as the source of effector cells. It was also tested for its ability to lyse 51Cr labelled human B cells in the presence of human serum as the source of complement. These tests were carried out as previously described for mouse monoclonal anti-carcinoma an~ibody L6, which can mediate ADCC, as well as complement-mediated cytoxicity, CDC. The techniques used and the data described for the L6 antibody have been previously described. Hellstrom, et al., Proc. Natl. Acad Sci. U.S.A. 83: 7059-7063 (1986).
Chimeric 2H7, but not mouse 2H7 antibody, will be able to mediate both ADCC and CDC against human B
lymphoma cells. Thus a hybridoma producing a non-functional mouse antibody can be converted to a hybridoma producing a chimeric antibody with ADCC and CDC activities. Such a chimeric antibody is a prime candidate for the treatment or imaging of B cell disorders, such as leukemias, lymphomas, and the like.
This invention therefore provides a method for making biologically functional antibodies when starting with a hybridoma which produces antibody which has the desired specificity for antigen but lacks biological effector functions such as ADCC and CDC.
Conclusions.
The results presented above demonstrate that the chimeric 2H7 antibody binds to (Bp35(CD20)) antigen positive human B cells to approximately the same extent as the mouse 2H7 monoclonal antibody. This is significant because the 2H7 antibody defines a surface phosphoprotein antigen (Bp35(CD20)), of about 35,000 daltons, which is expressed on the cells of B cell lineage. The 2H7 antibody does not bind detectably to various other cells such as fibroblasts, endothelial cells, or epithelial cells in the major organs or the stem cell precursors which give rise to B cells.

Although the prospect of attempting tumor therapy using monoclonal antibodies is attractive, with some partial tumor regressions being reported, to date such monoclonal antibody therapy has been met with limited success (Houghton et al., February 1985, Proc. Natl.
Acad. Sci. 82:1242-1246). Murine monoclonal anti-(Bp35(CD20)) antibody has been used for therapy of B cell malignancies (Press, et al.,) Blood: Feb.
1987, in press). The therapeutic efficacy of mouse monoclonal antibodies (which are the ones that have been tried so far) appears to be too low for most practical purposes. Because of the "human" properties which may make the chimeric 2H7 monoclonal antibodies more resistant to clearance and less immunogenic ln vivo, the chimeric 2H7 monoclonal antibodies will be advantageously used not only for therapy with unmodi-fied chimeric antibodies, but also for development of various immunoconjugates with drugs, toxins, immunomo-dulators, isotopes, etc., as well as for diagnostic purposes such as in vivo imaging of B-cell tumors (for example, lymphomas and leukemias) using appropriately labelled chimeric 2H7 antibodies. Such immunoconjuga-tion techniques are known to those skilled in the art and can be used to modify the chimeric 2H7 antibody molecules of the present invention. The chimeric 2H7 antibody, by virtue of its having the human constant portion, will possess biological activity in complement-dependent and antibody-dependent cytotoxicity which the mouse 2H7 does not.
An illustrative cell line secreting chimeric 2H7 antibody was deposited prior to the U.S. filing date at the ATCC, Rockville Maryland. This is a trans-fected hybridoma (corresponds to lD6 cells supra) ATCC
HB 9303.

The present invention is not to be limited in scope by the cell lines deposited since the deposited embodiment is intended as a single illustration of one aspect of the invention and all cell lines which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the in-vention in addition to those shown in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

_45- 1 336826 Binding Assays Of Chimeric 2H7 Antibody and Mouse 2H7 Mono-clonal Antibody to a B cell Line Expressing (Bp35(CD20)) and a Cell Line Not Expressing This Antigen.

Binding Ratio* for T51 B Cells Antibody GAM GAH

2H7 Mouse 37 ND
2H7 Chimeric ND 29 L6 Mouse 1 ND

Binding Ratio* for C3347 Cells GAM GAH
2H7 Mouse 1.4 ND
2H7 Chimeric ~D 1.3 L6 Mouse 110 ND

*All assays were conducted using an antibody concentration of lOug/ml. The binding ratio is the number of times brighter a test sample is than a control sample treated with GAM(FITC-Conjugated goat anti-mouse) or GAH (FITC conjugated goat anti-human) alone. A ratio of 1 means that the test sample is just as bright as the control; a ratio of 2 means the test sample is twice as bright as the control and so on.

ND - not done

Claims (15)

1. A chimeric antibody molecule comprising a human constant region and a non-human variable region, said antibody having the binding specificity and the cytolytic activity of a chimeric antibody produced by cell line ATCC HB 9303.

2. The chimeric antibody of claim 1, which is that in cell line ATCC HB 9303.

3. The chimeric antibody of claim 1, wherein said cytolytic activity is antibody-dependent cellular cytotoxicity.

4. The chimeric antibody of claim 1, wherein said cytolytic activity is complement-dependent cytolysis.

5. The chimeric antibody of claim 1 expressed in a eukaryotic host.

6. The chimeric antibody of claim 5, wherein said host is a yeast cell.

7. The chimeric antibody of claim 5, wherein said host is a mammalian cell.

8. The chimeric antibody of claim 1 in detectably labelled form.

9. The chimeric antibody of claim 1 immobilized on an aqueous-insoluble solid phase.

10. The chimeric antibody of claim 1 conjugated to a therapeutic selected from the group consisting of a drug, a toxin, an immunomodulator and a radioisotope.

11. A process for preparing a chimeric antibody comprising a human constant region and a non-human variable region comprising:
a) culturing a eukaryotic host capable of expressing said chimeric antibody under culturing conditions;
b) expressing said chimeric antibody; and c) recovering a chimeric antibody having the binding specificity and the cytolytic activity of a chimeric antibody produced by cell line ATCC HB 9303 from said culture.

12. The process of claim 11, wherein said host is cell ATCC HB 9303.

13. The process of claim 11, wherein said host is a yeast cell.

14. The process of claim 11, wherein said host is a mammalian cell.

15. A chimeric antibody produced by the process of claim 11.